Steven Roberds, PhD, chief scientific officer for TS Alliance, talks about the latest clinical trial the advocacy group is focused on to determine which children with tuberous sclerosis complex will develop seizures and whether early intervention can attenuate seizure activity as the child grows.

For more information, visit www.TSAlliance.org

свернуть